Ly49D-mediated ITAM signaling in immature thymocytes impairs development by bypassing the pre-TCR checkpoint.

Activating and inhibitory NK receptors regulate the development and effector functions of NK cells via their ITAM and ITIM motifs, which recruit protein tyrosine kinases and phosphatases, respectively. In the T cell lineage, inhibitory Ly49 receptors are expressed by a subset of activated T cells and by CD1d-restricted NKT cells, but virtually no expression of activating Ly49 receptors is observed. Using mice transgenic for the activating receptor Ly49D and its associated ITAM signaling DAP12 chain, we show in this article that Ly49D-mediated ITAM signaling in immature thymocytes impairs development due to a block in maturation from the double negative (DN) to double positive (DP) stages. A large proportion of Ly49D/DAP12 transgenic thymocytes were able to bypass the pre-TCR checkpoint at the DN3 stage, leading to the appearance of unusual populations of DN4 and DP cells that lacked expression of intracellular (ic) TCRβ-chain. High levels of CD5 were expressed on ic TCRβ(-) DN and DP thymocytes from Ly49D/DAP12 transgenic mice, further suggesting that Ly49D-mediated ITAM signaling mimics physiological ITAM signaling via the pre-TCR. We also observed unusual ic TCRβ(-) single positive thymocytes with an immature CD24(high) phenotype that were not found in the periphery. Importantly, thymocyte development was completely rescued by expression of an Ly49A transgene in Ly49D/DAP12 transgenic mice, indicating that Ly49A-mediated ITIM signaling can fully counteract ITAM signaling via Ly49D/DAP12. Collectively, our data indicate that inappropriate ITAM signaling by activating NK receptors on immature thymocytes can subvert T cell development by bypassing the pre-TCR checkpoint.

HLA-B7-Restricted EBV-Specific CD8+ T Cells Are Dysregulated in Multiple Sclerosis.

It was hypothesized that the EBV-specific CD8(+) T cell response may be dysregulated in multiple sclerosis (MS) patients, possibly leading to a suboptimal control of this virus. To examine the CD8(+) T cell response in greater detail, we analyzed the HLA-A2-, HLA-B7-, and HLA-B8-restricted EBV- and CMV-specific CD8(+) T cell responses in a high number of MS patients and control subjects using tetramers. Content in cytolytic granules, as well as cytotoxic activity, of EBV- and CMV-specific CD8(+) T cells was assessed. We found that MS patients had a lower or a higher prevalence of HLA-A2 and HLA-B7, respectively. Using HLA class I tetramers in HLA-B7(+) MS patients, there was a higher prevalence of MS patients with HLA-B*0702/EBV(RPP)-specific CD8(+) T cells ex vivo. However, the magnitude of the HLA-B*0702/EBV(RPP)-specific and HLA-B*0702/CMV(TPR)-specific CD8(+) T cell response (i.e., the percentage of tetramer(+) CD8(+) T cells in a study subject harboring CD8(+) T cells specific for the given epitope) was lower in MS patients. No differences were found using other tetramers. After stimulation with the HLA-B*0702/EBV(RPP) peptide, the production of IL-2, perforin, and granzyme B and the cytotoxicity of HLA-B*0702/EBV(RPP)-specific CD8(+) T cells were decreased. Altogether, our findings suggest that the HLA-B*0702-restricted viral (in particular the EBV one)-specific CD8(+) T cell response is dysregulated in MS patients. This observation is particularly interesting knowing that the HLA-B7 allele is more frequently expressed in MS patients and considering that EBV is associated with MS.

[Illustrations de Il Petrarcha] / [Non identifié] ; Pétrarque, aut. du texte

Comprend : [Frontispice : cariatides, putti et éléments d'architecture. Aigle avec devise : Semper Eadem.] [Cote : Res p Yd 113/Microfilm R 13186] ; [Fleuron en reg. folio i ii : portraits de Pétrarque et de Laure, en bas-reliefs sur une urne antique.] [Cote : Res p Yd 113/Microfilm R 13186] ; [Carte en reg. folio i iiiii : carte de la région de Valclusa.] [Cote : Res p Yd 113/Microfilm R 13186] ; [Fig. folio X ij : le triomphe de l'Amour ou Cupidon. Laure et Pétrarque.] [Cote : Res p Yd 113/Microfilm R 13186] ; [Fig. en reg. p.181 : le triomphe de la Chasteté.] [Cote : Res p Yd 113/Microfilm R 13186] ; [Fig. p.185 : le triomphe de la Mort.] [Cote : Res p Yd 113/Microfilm R 13186] ; [Fig. p.191 : le triomphe de la Gloire.] [Cote : Res p Yd 113/Microfilm R 13186] ; [Fig. en reg. p.204 : le triomphe du Temps.] [Cote : Res p Yd 113/Microfilm R 13186] ; [Fig. p.206 : le triomphe de la Divinité ou de l'Eternité. La Sainte Trinité, le Père, le Christ et le Saint-Esprit. Les Elus.] [Cote : Res p Yd 113/Microfilm R 13186] ; [Fig. p.216 : marque de l'imprimeur (?). Aigle et devise latine.] [Cote : Res p Yd 113/Microfilm R 13186]

[Illustrations de Art de chevalerie] / [Non identifié] ; Johann Hacobi von Wallhausen, aut. du texte

Comprend : [Frontispice : éléments d'architecture, figures de deux soldats en armure, scène de charge de cavalerie.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.68 (ou 446) : art équestre. Manière de monter à cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.72 (ou 452) : art équestre. Manière de faire tourner le cheval en une ronde ou dans une figure serpentine.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.78 (ou 460) : art équestre. Manière de faire monter une côte à un cheval, de lui faire sauter un obstacle.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.80 (ou 464) : art équestre. Manière de faire traverser un fleuve à un cheval, de lui faire traverser un pont étroit et de lui faire dominer sa peur du feu. ] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.84 (ou 470) : art équestre. Manière de combattre avec un lance sur un cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.86 (ou 474) : art équestre. Manière de combattre avec un lance ou avec une épéesur un cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.88 (ou 478) : art équestre. Manière de combattre avec des arquebuses sur un cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.90 (ou 482) : art équestre. Manière de combattre avec des arquebuses ou des épées sur un cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.94 (ou 488) : art équestre. Manière de combattre entre un fantassin et un cavalier.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.96 (ou 492) : art équestre. Manière de combattre entre un fantassin et un cavalier ou entre deux cavalier armés d'épées.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.100 (ou 498) : art équestre. Manière de combattre entre cavaliers.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.102 (ou 502) : art équestre. Manière de combattre entre deux adversaires à pied.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.106 (ou 508) : art équestre. Scène de batailel avec charge de cavalerie.] [Cote : Res Z Fontanieu 103 (5)] ; [Vigentte p.512 : marque d'imprimeur.] [Cote : Res Z Fontanieu 103 (5)]

Prognostic relevance of Masaoka and Müller-Hermelink classification in patients with thymic tumors.

BACKGROUND: To compare the prognostic relevance of Masaoka and Müller-Hermelink classifications. METHODS: We treated 71 patients with thymic tumors at our institution between 1980 and 1997. Complete follow-up was achieved in 69 patients (97%) with a mean follow up-time of 8.3 years (range, 9 months to 17 years). RESULTS: Masaoka stage I was found in 31 patients (44.9%), stage II in 17 (24.6%), stage III in 19 (27.6%), and stage IV in 2 (2.9%). The 10-year overall survival rate was 83.5% for stage I, 100% for stage IIa, 58% for stage IIb, 44% for stage III, and 0% for stage IV. The disease-free survival rates were 100%, 70%, 40%, 38%, and 0%, respectively. Histologic classification according to Müller-Hermelink found medullary tumors in 7 patients (10.1%), mixed in 18 (26.1%), organoid in 14 (20.3%), cortical in 11 (15.9%), well-differentiated thymic carcinoma in 14 (20.3%), and endocrine carcinoma in 5 (7.3%), with 10-year overall survival rates of 100%, 75%, 92%, 87.5%, 30%, and 0%, respectively, and 10-year disease-free survival rates of 100%, 100%, 77%, 75%, 37%, and 0%, respectively. Medullary, mixed, and well-differentiated organoid tumors were correlated with stage I and II, and well-differentiated thymic carcinoma and endocrine carcinoma with stage III and IV (p < 0.001). Multivariate analysis showed age, gender, myasthenia gravis, and postoperative adjuvant therapy not to be significant predictors of overall and disease-free survival after complete resection, whereas the Müller-Hermelink and Masaoka classifications were independent significant predictors for overall (p < 0.05) and disease-free survival (p < 0.004; p < 0.0001). CONCLUSIONS: The consideration of staging and histology in thymic tumors has the potential to improve recurrence prediction and patient selection for combined treatment modalities.

Inflammatory role of ASC in antigen-induced arthritis is independent of caspase-1, NALP-3, and IPAF.

Because IL-1beta plays an important role in inflammation in human and murine arthritis, we investigated the contribution of the inflammasome components ASC, NALP-3, IPAF, and caspase-1 to inflammatory arthritis. We first studied the phenotype of ASC-deficient and wild-type mice during Ag-induced arthritis (AIA). ASC(-/-) mice showed reduced severity of AIA, decreased levels of synovial IL-1beta, and diminished serum amyloid A levels. In contrast, mice deficient in NALP-3, IPAF, or caspase-1 did not show any alteration of joint inflammation, thus indicating that ASC associated effects on AIA are independent of the classical NALP-3 or IPAF inflammasomes. Because ASC is a ubiquitous cytoplasmic protein that has been implicated in multiple cellular processes, we explored other pathways through which ASC may modulate inflammation. Ag-specific proliferation of lymph node and spleen cells from ASC-deficient mice was significantly decreased in vitro, as was the production of IFN-gamma, whereas IL-10 production was enhanced. TCR ligation by anti-CD3 Abs in the presence or absence of anti-CD28 Abs induced a reduction in T cell proliferation in ASC(-/-) T cells compared with wild-type ones. In vivo lymph node cell proliferation was also significantly decreased in ASC(-/-) mice, but no effects on apoptosis were observed either in vitro or in vivo in these mice. In conclusion, these results strongly suggest that ASC modulates joint inflammation in AIA through its effects on cell-mediated immune responses but not via its implication in inflammasome formation.

Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies.

Peptide Ags presented by class I MHC molecules on human melanomas and that are recognized by CD8(+) T cells are the subjects of many studies of antitumor immunity and represent attractive candidates for therapeutic approaches. However, no direct quantitative measurements exist to reveal their expression hierarchy on the cell surface. Using novel recombinant Abs which bind these Ags with a peptide-specific, MHC-restricted manner, we demonstrate a defined pattern of expression hierarchy of peptide-HLA-A2 complexes derived from three major differentiation Ags: gp100, Melan-A/Mart-1, and tyrosinase. Studying melanoma cell lines derived from multiple patients, we reveal a surprisingly high level of presentation of tyrosinase-derived complexes and moderate to very low expression of complexes derived from other Ags. No correlation between Ag presentation and mRNA expression was found; however, protein stability may play a major role. These results provide new insights into the characteristics of Ag presentation and are particularly important when such targets are being considered for immunotherapy. These results may shed new light on relationships between Ag presentation and immune response to cancer Ags.

Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.

CD8(+) CTLs play a critical role in antitumor immunity. However, vaccination with synthetic peptide containing CTL epitopes has not been generally effective in inducing protective antitumor immunity. In this study, we addressed the detailed mechanism(s) involved in this failure using a new tumor model of BALB/c transplanted tumors expressing NY-ESO-1, an extensively studied human cancer/testis Ag. Whereas peptide immunization with an H2-D(d)-restricted CTL epitope derived from NY-ESO-1 (NY-ESO-1 p81-88) induced NY-ESO-1(81-88)-specific CD8(+) T cells in draining lymph nodes and spleens, tumor growth was significantly enhanced. Single-cell analysis of specific CD8(+) T cells revealed that peptide immunization caused apoptosis of >80% of NY-ESO-1(81-88)-specific CD8(+) T cells at tumor sites and repetitive immunization further diminished the number of specific CD8(+) T cells. This phenomenon was associated with elevated surface expression of Fas and programmed death-1. When peptide vaccination was combined with an adjuvant, a TLR9 ligand CpG, the elevated Fas and programmed death-1 expression and apoptosis induction were not observed, and vaccine with peptide and CpG was associated with strong tumor growth inhibition. Selection of appropriate adjuvants is essential for development of effective cancer vaccines, with protection of effector T cells from peptide vaccine-induced apoptosis being a prime objective.

Objective Sleep Structure and Cardiovascular Risk Factors in the General Population: The HypnoLaus Study.

STUDY OBJECTIVES: To evaluate the association between objective sleep measures and metabolic syndrome (MS), hypertension, diabetes, and obesity. DESIGN: Cross-sectional study. SETTING: General population sample. PARTICIPANTS: There were 2,162 patients (51.2% women, mean age 58.4 ± 11.1). INTERVENTIONS: Patients were evaluated for hypertension, diabetes, overweight/obesity, and MS, and underwent a full polysomnography (PSG). MEASUREMENTS AND RESULTS: PSG measured variables included: total sleep time (TST), percentage and time spent in slow wave sleep (SWS) and in rapid eye movement (REM) sleep, sleep efficiency and arousal index (ArI). In univariate analyses, MS was associated with decreased TST, SWS, REM sleep, and sleep efficiency, and increased ArI. After adjustment for age, sex, smoking, alcohol, physical activity, drugs that affect sleep and depression, the ArI remained significantly higher, but the difference disappeared in patients without significant sleep disordered breathing (SDB). Differences in sleep structure were also found according to the presence or absence of hypertension, diabetes, and overweight/obesity in univariate analysis. However, these differences were attenuated after multivariate adjustment and after excluding subjects with significant SDB. CONCLUSIONS: In this population-based sample we found significant associations between sleep structure and MS, hypertension, diabetes, and obesity. However, these associations were cancelled after multivariate adjustment. We conclude that normal variations in sleep contribute little if any to MS and associated disorders.

Recueil d'arbres généalogiques, avec blasons coloriés, relatifs, en majeure partie, à des familles de la Flandre et de l'Artois.

Contient : Copie de l'acte de nomination d'Antoine de Beaulincourt, comme roi d'armes de l'Ordre de la Toison d'Or (1550) ; Table alphabétique